Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up

Antiviral Therapy

Volumn 6, Issue 1, 2001, Pages 21-39

  Vandamme, A M ^a   Houyez, F ^b   Banhegyi D ^c   Clotet, B ^d   De Schrijver, G ^e   De Smet, K A L ^f   Hall, W W ^g   Harrigan, R ^e,h   Hellmann, N ⁱ   Hertogs, K ^e,j   Holtzer, C ^k   Larder, B ^e,j   Pillay, D ^l   Race, E ^e,m   Schmit, J C ⁿ   Schuurman, R ^o   Shulse, E ^p   Sonnerborg A ^q   Miller, V ^r  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Vaincre Le Sida   (France)

^c Addiktológiai és Pszichiátriai Ambulancia   (Hungary)

^d Irsicaixa AIDS Research Institute   (Spain)

^e Innogenetics ^*  (France)

^f INNOGENETICS   (Belgium)

^g UNIVERSITY COLLEGE DUBLIN   (Ireland)

^h BC Center for Excellence in HIV/AIDS   (Canada)

ⁱ MONOGRAM BIOSCIENCES   (United States)

^j Virco BVBA   (Belgium)

^k Visible Genetics   (France)

^l UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^m BICHAT HOSPITAL   (France)

ⁿ CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^o UTRECHT UNIVERSITY   (Netherlands)

^p APPLIED BIOSYSTEMS   (United States)

^q KAROLINSKA INSTITUTE   (Sweden)

^r GOETHE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; DRUG EFFECT; FOLLOW UP; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIOLOGICAL EXAMINATION; PHENOTYPE; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; STANDARD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DRUG RESISTANCE, MICROBIAL; FOLLOW-UP STUDIES; GENOTYPE; GUIDELINES; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; QUALITY CONTROL;

EID: 0008730523     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (157)

1. Miller V, Vandamme A-M, Loveday C, Staszewski S, Lundgren J, Youle M, Ait-Khaled M, Boucher C, Brun-Vézinet F, Dedes N, Giaquinto C, Hertogs K, Houyez F, Perrin L, Pillay D, Schmit J-C, Schuurman R & Lange JM. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001; 15:309-320.
2. Youle M, Holtzer C, Simpson K, de Clerq K & Miller V, HIV-1 drug resistance testing: health outcomes issues. Antiviral Therapy 2000; 5:113-115.
3. Miller V. European guidelines on resistance testing: why are they needed? HIV Medicine 2000 1:129-131.
4. Vandamme A-M, Witvrouw M, Pannecouque C, Balzarini J, Van Laethem K, Schmit JC, Desmyter J & De Clercq E. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In Methods in Cellular and Molecular Medicine: Antiviral Chemotherapy Edited by D Kinchington & RF Schinazi. 1999; Totowa, NJ: The Humana Press Inc. pp. 223-258.
5. Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, Rimland D, Schinazi RF & Rossau R. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrobial Agents & Chemotherapy 1997; 41:284-291.
6. Larder BA, Kellam P & Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991; 5:137-144.
7. Kaye S, Loveday C & Tedder RS. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. Journal of Medical Virology 1992; 37:241-246.
8. Gunthard HF, Wong JK, Ignacio CC, Havlir DV & Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Research and Human Retroviruses 1998; 14:869-876.
9. nd Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt, Germany, 25-27 February 2000.
10. Collin G, Descamps D, Telles F, Matheron S, Obry V, Costagliola D & Brun-Vézinet F. Differences in protease and reverse transcriptase sequences between the TruGene HIV-1 genotyping kit (Visible Genetics) and the ViroSeq genotyping system (PE Applied Biosystems). Antiviral Therapy 2000; 5 (Suppl. 3):53.
11. Wilson JW, Bean P, Robins T, Graziano F & Parsing DH. Comparative evaluation of three human immunodeficiency virus genotyping systems. Journal of Clinical Microbiology 2000; 38:3022-3028.
12. Shao X, Ekstrand DHL, Bhikhabhai R, Kallander CF & Gronowitz JS. A non-radioactive microtitre plate reverse transcriptase (RT) assay, based on immobilized template, for screening of RT activity inhibitors and evaluation of their mode of action. Antiviral Chemistry & Chemotherapy 1997; 8:149-159.
13. Von der Helm K, Seelmeier S, Kisselev A & Nitschko H. Identification, purification and cell culture assays of retroviral proteases. In Retroviral Proteases. Edited by LC Kuo & JA Shafer. 1994; 89-105. New York: Academic Press.
14. Kellam P & Larder BA. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrobial Agents & Chemotherapy 1994; 38:23-30.
15. Maschera B, Furfine E & Blair ED. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. Journal of Virology 1995; 69:5431-5436.
16. Hertogs K, de Béthune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B & Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrobial Agents & Chemotherapy 1998; 42:269-276.
17. Walter H, Schmidt B, Korn K, Vandamme, A-M, Harrer T & Uberla K. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. Journal of Clinical Virology 1999; 13:71-80.
18. Parkin NT, Lie YS, Hellmann N, Markowitz M, Bonhoeffer S, Ho DD & Petropoulos CJ. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. Journal of Infectious Diseases 1999; 180:865-870.
19. Zennou V, Mammano F, Paulous S, Mathez D & Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. Journal of Virology 1998; 72:3300-3306.
20. Qari SH, Respess R, Weinstock H, Beltrami E, Hertogs K, Larder BA, Petropoulos CJ, Hellman N & Heneine W. A comparative analysis of Virco Antivirogram and ViroLogic PhenoSense phenotypic assays for drug susceptibility of HIV-1. Antiviral Therapy 2000; 5 (Suppl. 3):49.
21. Van Laethem K, Van Vaerenbergh K, Schmit J-C, Sprecher S, Hermans P, De Vroey V, Schuurman R, Harrer T, Witvrouw M, Van Wijngaerden E, Stuyver L, Van Ranst M, Desmyter J, De Clercq E & Vandamme A-M. Phenotypic assays and sequencing are less sensitive than point mutation assays for the detection of resistance in mixed HIV-1 genotypic populations. Journal of AIDS 1999; 22:107-118.
22. Villahermosa ML, Contreras G, Péres-Alvarez L, Bru E, Medrano L, Delgado E, Colomo C, Thomson M & Najera R. Evaluation of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors. Antiviral Therapy 1998; 3:221-228.
23. Shafer RW, Winters MA, Mayers DL, Japour AJ, Kuritzkes DR, Weislow OS, White F, Erice A, Sannerud KJ, Iversen A, Pena F, Dimitrov D, Frenkel LM & Reichelderfer PS. Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group. Journal of Clinical Microbiology 1996; 34:1849-1853.
24. Puchhammer-Stockl E, Schmied B, Mandl CW, Vetter N & Heinz FX. Comparison of line probe assay (LiPA) and sequence analysis for detection of HIV-1 drug resistance. Journal of Medical Virology 1999; 57:283-289.
25. Schuurman R, Brambilla D, de Groot T & Boucher C. Second worldwide evaluation of HIV-1 drug resistance genotyping quality using the ENVA 2 panel. Antiviral Therapy 1999: 4 (Suppl. 1):41 (Abstr. 58).
26. Schmit J-C, Ruiz L, Stuyver L, Van Laethem K, Vanderunden I, Puig T, Rossau R, Desmyter J, De Clercq E, Clotet B & Vandamme A-M. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. Journal of Virological Methods 1998; 73:77-82.
27. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ & Whitcomb JM. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 2000; 44:920-928.
28. Kolberg J, Thompson M, Baxter J, Dehlinger M, Howard S, Zamroud M, Mayers D & Neaton J. Low levels of preexisting mutant virus blunts HIV-1 response to therapy. Antiviral Therapy 2000; 5:144. (Abstr. 17.)
29. De Béthune M-P, Hertogs K, Heyndrickx J, Fransen K, Azijn H, Michiels L, Janssens W, Scholliers A, Larder B, Bloor S, Pauwels R & van der Groen G. Does natural or acquired resistance to reverse transcriptase and protease inhibitors, observed in HIV-1 groups M (subtypes A-H) and O, differ from subtype B? Antiviral Therapy 1999: 4 (Suppl. 1):33. (Abstr. 49.)
30. Vahey M, Nau ME, Barrick S, Cooley JD, Sawyer R, Sleeker AA, Vickerman P, Bloor S, Larder B, Michael NL & Wegner SA. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. Journal of Clinical Microbiology 1999; 37:2533-2537.
31. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV & Richman DD. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral cherapy. Journal of Virology 1998; 72:2422-2428.
32. Kaye S, Comber E, Tenant FM & Loveday C. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Research and Human Retroviruses 1995; 11:1221-1225.
33. Erice A, Li W, Henry K & Balfour HH. HIV drug resistance mutations in plasma closely represent viral sequences in lymphoid tissue. Antiviral Therapy 1999: 4 (Suppl. 1):48. (Abstr. 70.)
34. Havlir DV & Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Annals of Internal Medicine 1996; 124:984-994.
35. Sharma PL & Crumpacker CS. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. Journal of Virology 1997; 71:8846-8851.
36. Boyer PL & Hughes SH. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 1995; 39:1624-1628.
37. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH & Berkhout B. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO Journal 1996; 15:4040-4049.
38. Ueno T, Shirasaka T & Mitsuya H. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. Journal of Biological Chemistry 1995; 270:23605-23611.
39. Verhofstede C, Van Wanzeele F, Van Der Gucht B, De Cabopter N & Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999; 13:2541-2546.
40. Devereux HL. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13:F123-F127.
41. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. LB10.
42. Aquaro S, Calio R, Balestra E, Bagnarelli P, Cenci A, Bertoli A, Tavazzi B, Di Pierro D, Francesconi M, Abdelahad D & Perno CF. Clinical implications of HIV dynamics and drug resistance in macrophages. Journal of Biological Regulators and Homeostatic Agents 1998; 12:23-27.
43. Eron JJ, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F, Alcorn TM, Fiscus SA & Cohen MS. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 1998; 12:F181-F189.
44. De Pasquale MP, Rosenberg E, Quayle A, Tremblay C, Martinez-Picado J, Allega J, Sutton L, Shi L, Savara AV, Boswell S, Sax P, Hirsch M, Caliendo A, Anderson D, Walker BD & D'Aquila RT. Primary HIV infection: in vivo fitness of pre-therapy resistant mutants and potential for secondary spread of HIV from semen. Antiviral Therapy 1999; 4 (Suppl. 1):89. (Abstr. 126.)
45. Kiessling AA, Fitzgerald LM, Zhang D, Chay H, Brettler D, Eyre RC, Steinberg J, McGowan K & Byrn RA. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Research and Human Retroviruses 1998; 14 (Suppl. 1):S33-S41.
46. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ & Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 1999; 43:1817-1826.
47. Strappe PM, Bell JE & Simmonds P. Persistence of drug-resistant variants of HIV-1 in the brain following combination therapy. AIDS Weekly 1999; 15.
48. Van Vaerenbergh K, Van Laethem K, Albert J, Boucher CA, Clotet B, Florida M, Gerstoft J, Heijdeman B, Nielsen C, Pannecouque C, Perrin L, Pirillo MF, Ruiz L, Schmit J-C, Schneider F, Schoolmeester A, Schuurman R, Steilbrink HJ, Stuyver L, Van Lunzen J, Van Remoortel B, Van Wijngaerden E, Vella S, Witvrouw M, Yerly S, De Clercq E, Desmyter J & Vandamme A-M. Prevalence and characteristics of multinucleoside-resistant HIV-1 among European patients receiving combinations of nucleoside analogues. Antimicrobial Agents & Chemotherapy 2000; 44:2109-2117.
49. Vandamme A-M, Van Laethem K & De Clercq E. Managing resistance to anti-HIV drugs. An important consideration for effective disease management. Drugs 1999; 57:337-361.
50. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T & Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. Journal of Clinical Microbiology 1999; 37:2291-2296.
51. Hertogs K, Zolopa A, Bloor S, Shafer B, De Vroey V, Warford A, Larder B & Merigan T. A blinded comparative analysis of two genotyping service laboratories: full sequence analysis of HIV-1 protease and reverse transcriptase. Antiviral Therapy 1999; 4 (Suppl. 1):59. (Abstr. 87.)
52. Harrigan PR, Verbiest W, Larder B, Hertogs K, Tilley J, Raboud J & Montaner J. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy. Antiviral Therapy 2000; 5 (Suppl. 3):68 (Abstr. 86).
53. Bacheler L, Ploughman L, Hertogs K & Larder B. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naive patients (study DMP 266-006). Antiviral Therapy 2000; 5 (Suppl. 3):70 (Abstr. 88).
54. Miller V, Cozzi Lepri A, Hertogs K, Gute P, Larder B, Bloor S, Klauke S, Rabenau H, Phillips A & Staszewski S. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antiviral Therapy 2000; 5:49-55.
55. Harrigan PR, Hertogs K, Verbiest W, Pauwels R, Larder B, Kemp S, Bloor S, Yip B, Hogg R, Alexander C & Montaner JS. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13:1863-1871.
56. Kempf D, Brun S, Rode R, Isaacson J, King M, Xu Y, Real K, Hsu A, Granneman R, Lie Y, Hellmann N, Bernstein B & Sun E. Identification of clinically relevant phenotypic and genotypic breakpoints for ABT-378/r in multiple PI-experienced, NNRTI-naive patients. Antiviral Therapy 2000; 5 (Suppl. 3):70 (Abstr. 89).
57. Calvez V, Costagliola D, Descamps D, Matheron S, Simon A, Valantin M-A, Katlama C & Brun-Vézinet F. Resistance and viral response to stavudine/lamivudine combination in zidovudine, didanosine and zalcitabine experienced patients in the ALTIS 2 ANRS trial. Antiviral Therapy 2000; 5 (Suppl. 3):83 (Abstr. 107).
58. Schinazi RF, Larder B & Mellors JW. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. International Antiviral News 2000; 8:65-91.
59. Menéndez-Arias L & Domingo E. Amino acid substitutions associated with resistance to HIV-1 reverse transcriptase and protease inhibitors. In Guide to management of HIV resistance and pharmacokinetics of drug therapy. Edited by B Clotet, L Menénendez-Anas, L Ruiz, C Tural, A-M Vandamme, D Burger, JM Shapiro, CA Boucher, R D'Aquila & DD Richman. 2000; pp. 31-53. Barcelona, Spain: Editorial TAISA.
60. Shafer RW, Kantor R & Gonzales MJ. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Reviews 2000; 2:211-228.
61. Shafer RW, Stevenson D & Chan B. Human Immunodeficiency Virus reverse transcriptase and protease sequence database. Nucleic Acids Research 1999; 27:348-352.
62. Larder BA, Kemp SD & Hertogs K. Quantitative predicnon of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (Vitual Phenotype). Antiviral Therapy 2000; 5 (Suppl. 3):49 (Abstr. 63).
63. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., USA, 26-29 September 1999. Abstr. 421.
64. Schmidt B, Walter H, Moschik B, Paatz C, Van Vaerenbergh K, Vandamme A-M, Schmitt M, Harrer T, Helm M, Uberla K & Korn K. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS 2000; 14:1731-1738.
65. Mendéndez-Arias L & Domingo E. Sensitivity to reverse transcriptase and protease inhibitors of recombinant HIV clones harbouring resistance mutations: in vitro studies. In Guide to management of HIV resistance and pharmacokinetics of drug therapy. Edited by Clotet B, Menéndez-Arias L, Ruiz L, Tural C, Vandamme A-M, Burger D, Shapiro JM, Boucher CA, D'Aquila R & Richman DD. 2000; pp. 55-84. Barcelona, Spain: Editorial TAISA, S.L.
66. 65a. Vandamme A-M. Possible genotypic and phenotypic algorithm for the clinical use of HIV-1 drug resistance testing. In Guide to management of HIV resistance and pharmacokinetics of drug therapy. Edited by Clotet B, Menéndez-Arias L, Ruiz L, Tural C, Vandamme A-M, Burger D, Shapiro JM, Boucher CA, D'Aquila R & Richman DD. 2000; pp. 85-89. Barcelona, Spain: Editorial TAISA, S.L.
67. Tanuri A, Vicente ACP, Otsuki K, Ramos CA, Ferreira OC, Schechter M, Janini LM, Pieniazek D & Rayfield MA. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Antimicrobial Agents & Chemotherapy 1999; 43:253-258.
68. Palmer S, Alaeus A, Albert J & Cox S. Drug susceptibility of subtypes A, B, C, D and E human immunodeficiency virus type 1 primary isolates. AIDS Research and Human Retroviruses 1998; 14:157-162.
69. Shafer RW, Chuang TK, Hsu P, White CB & Katzenstein DA. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Research and Human Retroviruses 1999; 15:65-69.
70. Vandamme AM, Debyser Z, Pauwels R, De Vreeze K, Goubau P, Youle M, Gazzard B, Stoffels PA, Cauwenbergh GF, Anne J, Andries K, Janssen PAJ, Desmyter J & De Clercq E. Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. AID Research and Human Retroviruses 1994; 10:39-46.
71. Cox SW, Apéria K, Albert J & Wahren B. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Research and Human Retroviruses 1994; 10:1725-1729.
72. Apetrei C, Descamps D, Collin G, Loussert-Ajaka I, Damond F, Duca M, Simon F & Brun-Vézinet F. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. Journal of Virology 1998; 72:3534-3538.
73. Descamps D, Collin G, Letourneur F, Apetrei C, Damond F, Loussert-Ajaka I, Simon F, Saragosti S & Brun-Vézinet F. Susceptibility of human immunodeficiency virus type 1 group 0 isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. Journal of Virology 1997; 71:8893-8898.
74. St.Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD & Larder BA. Resistance to ddI and sensitivity to AZT-induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-1559.
75. Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao JQ, Chen ISY, Stevenson M & Tarpley WG. A mutation in reverse transcriptase of bis(heteroaryl) piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proceedings of the National Academy of Sciences, USA 1993; 90:4713-4717.
76. Larder BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to non-nucleoside reverse transcriptase inhibitors. Antimicrobial Agents & Chemotherapy 1992; 36:2664-2669.
77. Larder BA, Kemp SD & Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.
78. Nijhuis M, Schuurman R, de Jong D., van Leeuwen R., Lange J, Danner S, Keulen W, de Groot T & Boucher CA. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. Journal of Infectious Diseases 1997; 176:398-405.
79. Schmit J-C, Martinez-Picado J, Ruiz L, Tural C, Van Laethem K, Cabrera C, Ibanez A, Puig T, Witvrouw M, Desmyter J, De Clercq E, Clotet B & Vandamme A-M. Evolution of HIV drug resistance in zidovudine/zalcitabine-and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy. Antiviral Therapy 1998; 3:81-88.
80. Tachedjian G, Mellors J, Bazmi H, Birch C & Mills J. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. Journal of Virology 1996; 70:7171-7181.
81. Schmit J-C, Cogmaux J, Hermans P, Van Vaeck C, Sprecher S, Van Remoortel B, Witvrouw M, Balzarini J, Desmyter J, De Clercq E & Vandamme A-M. Multiple drug resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. Journal of Infectious Diseases 1996; 174:962-968.
82. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, Katzenstein DA & Mengan TC. A 6-base-pair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. Journal of Clinical Investigation 1998; 102:1769-1775.
83. Balzarini J, Karlsson A, Pérez-Pérez M-J, Camarasa M-J, Tarpley WG & De Clercq E. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. Journal of Virology 1993; 67:5353-5359.
84. Boyer PL, Lisziewicz J, Lori F & Hughes SH. Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase. Journal of Molecular Biology 1999; 286:995-1008.
85. De Jong JJ, Goudsmit J, Lukashov V, Hillebrand ME, Baan E, Huismans R, Danner SA, ten Veen JH, de Wolf F & Jurriaans S. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 1999; 13:75-80.
86. Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, Miller V, Sturmer M, Staszewski S, Ren J, Stammers DK, Stuart DI & Pauwels R. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrobial Agents & Chemotherapy 1999; 43:1961-1967.
87. Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B & Merigan TC. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. Journal of Virology 1996; 70:1086-1090.
88. Schmit J-C, Van Laethem K, Ruiz L, Hermans P, Sprecher S, Sonnerborg A, Leal M, Harrer T, Clotet B, Arendt V, Lissen E, Witvrouw M, Desmyter J, De Clercq E & Vandamme A-M. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998; 12:2007-2105.
89. Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R, Katzman M, Fiscus S & Merigan TC. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. Journal of Infectious Diseases 1994; 169:722-729.
90. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R & Mitsuya H. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceedings of the National Academy of Sciences, USA 1995; 92:2398-2402.
91. Tamalet C, Izopet J, Koch N, Fantini J & Yahi N. Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy. AIDS 1998; 12:F161-F166.
92. Van Laethem K, Witvrouw M, Balzarini J, Schmit J-C, Sprecher S, Hermans P, Leal M, Harrer T, Ruiz L, Clotet B, Van Ranst M, Desmyter J, De Clerq E & Vandamme A-M. Patient HIV-1 strains carrying the multiple nucleoside analogue resistance mutations are cross-resistant to abacavir. AIDS 2000; 14:469-471.
93. Fontaine E, Van Vaerenbergh K, Vandamme A-M & Schmit J-C. Multidrug-resistant human immunodeficiency virus type 1. AIDS Reviews 2000; 1:231-237.
94. Calvez V, Monroux M, Yvon A, Delaugerre C, Bossi P, Valantin MA, Coutellier A, Bonmarchand M, Huraux J-M, and Katlama C. Zidovudine resistance associated mutations can be selected in patients after long-term exposure to stavudine. Antiviral Therapy 1999; 4 (Suppl. 1):26. (Abstr. 38.)
95. de Mendoza C, Soriano V, Briones C, Gallego O, Barreiro P, Alvarez A & Gonzalez Lahoz J. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine. Journal of Acquired Immune Deficiency Syndrome 2000; 23:279-81.
96. Kemp S, Bloor S, Van Cauwenberge A., De Koning I, Van den Eynde C, Larder B, & Hertogs K. Analysis of 5000 HIV-1 clinical samples reveals complex non-nucleoside RT inhibitor resistance patterns. Antiviral Therapy 1999; 4 (Suppl. 1):20. (Abstr. 26.)
97. Lin PE, Gonzalez CJ, Griffith B, Friedland G, Calvez V, Ferchal F, Schinazi RF, Shepp DH, Ashraf AB, Wainberg MA, Soriano V, Mellors JW & Colonno RJ. Stavudine resistance: an update on susceptibility following prolonged therapy. Antiviral Therapy 1999; 4:21-28.
98. Lorenzi P, Yerly S, Abderrakim K, Fathi M, Rutschmann OT, Vonoverbeck J, Leduc D, Perrin L, Hirschel B, Battegay M, Burgisser P, Doorly R, Egger M, Erb P, Fierz W, Flepp M, Francioli P, Grob P, Gruninger U, Ledergerber B, Luthy R, Malinverni R, Matter L, Opravil M, Paccaud F, Pichler W, Rickenbach M, Ruschmann O & Vernazza P. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997; 11:F95-F99.
99. Mayers D. Rational approaches to resistance: nucleoside analogues. AIDS 1996; 10 (Suppl. 1):S9-13.
100. Ross L, Danehower S, Johnson M, Shaeffer M, Fisher R, Castillo S, Liao Q, Sawyer G, Keller A, Kline M & St Clair M. Stavudine-based combination and monotherapy selects for zidovudine resistance HIV-1 mutations in zidovudine-naive adults and in paediatric patients. Antiviral Therapy 1999; 4 (Suppl. 1):79. (Abstr. 115.)
101. Tisdale M. HIV protease inhibitors - resistance issues. International Antiviral News 1996; 4:41-43.
102. Venturi G, Romano L, Catucci M, Riccio ML, De Milito A, Gonnelli A, Rubino M, Valensin PE & Zazzi M. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse transcriptase inhibitors. European Journal of Clinical Microbiology and Infectious Diseases 1999; 18:274-282.
103. Shafer RW, Winters MA, Palmer S & Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Annals of Internal Medicine 1998; 128:906-911.
104. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J & Larder BA. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. Journal of Infections Diseases 1992; 165:105-110.
105. Caliendo AM, Savara A, An D, DeVore K, Kaplan JC & D'Aquila RT. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. Journal of Virology 1996; 70:2146-2153.
106. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo H-M, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CAB, Leonard JM, Norbeck DW & Kempf DJ. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 1996; 2:760-766.
107. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnick S & Boucher CA. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13:2349-2359.
108. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M & Volberding PA. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. Journal of Infectious Diseases 1999; 179:1375-1381.
109. Demeter LM, DeGruttola V, Eshleman SH, Jackson JB, Squires K, Fischl M, Hughes M & Hammer SM. Baseline genotypic predictors of virological outcome in a clinical trial of indinavir plus zidovudine plus lamivudine (ACTG 320). Antiviral Therapy 1999; 4 (Suppl. 1):48 (Abstr. 69).
110. Leigh Brown AJ, Gunthard HF, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR & Richman DD. Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy. Journal of Infectious Diseases 1999; 180:1043-1049.
111. Merigan TC, Hirsch RL, Fisher AC, Meyerson LA, Goldstein G & Winters MA. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. AIDS 1996; 10:159-165.
112. Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F & Kazatchkine MD. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999; 13:F71-F77.
113. Rey D, Hughes M, Pi JT, Winters M, Merigan TC & Katzenstein DA. HIV-1
114. Van Vaerenbergh K, Van Laethem K, Van Wijngaerden E, Schmit J-C, Schneider F, Ruiz L, Clotet B, Verhofstede C, Van Wanzeele F, Muyldermans , Simons P, Stuyver L, Hermans P, Evans C, De Clercq E, Desmyter J & Vandamme A-M. Baseline HIV Type-1 genotypic resistance to a newly added nucleoside analog is predictive for virologic failure of the new therapy. AIDS Research and Human Retroviruses 2000; 16:529-537.
115. Zolopa AR, Shafer RW, Warford A, Montoya JG, Katzenstein D & Merigan TC. Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. Antiviral Therapy 1998; 3 (Suppl. 1):37.
116. De Gruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lamer R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L & Mellors I. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5:41-48.
117. Katzenstein TL, Jorgenson LB, Nielsen H, Kirk O, Schuurman R, Nielsen C & Gerstoft J. Lack of obvious interplay between baseline genotype and virological response among protease inhibitor-naive patients treated with HAART. Antiviral Therapy 1999; 4 (Suppl. 1):68 (Abstr. 104).
118. Katlama C, Duvivier C, Mouroux M, Legrand M, Chiesa E, Schneider L, Ait-Mohand H, Agher R, Coutellier A, Fievet MH, Race E, Clavel F & Calvez V. GIGHAART: a rescue therapy for HIV patients with multiple HAART failures. Antiviral Therapy 1999; 4 (Suppl. 1):77 (Abstr. 113).
119. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 731.
120. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 788.
121. Durant J, Clevenbergh P, Halfon P, Delguidice P, Porsin S, Simonet P, Montagne N, Boucher CAB, Schapiro JM & Dellamonica P. Drug resistance genotyping in HIV-1 therapy: the viradapt randomised controlled trial. Lancet 1999; 353:2195-2199.
122. Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro JM, Boucher CAB & Dellamonica P. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART: the Viradapt study, week 48 follow-up. Antiviral Therapy 2000; 5:65-70.
123. Baxter JD, Mayers DL, Wentworth DN, Neaton JD & Merigan TC. Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genorypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. AIDS 2000; 14:F83-F93
124. th Interdisciplinary Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000. Abstr. L-10.
125. Cohen C, Kessler H, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart A & Graham N. Phenotypic resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA 3001). Antiviral Therapy 2000; 5 (Suppl. 3):67.
126. Meynard JL, Vray M, Morand-Joubert L, Matheron S, Peytavin G, Clavel F, Brun-Vézinet F & Girard PM. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antiviral Therapy 2000; 5 (Suppl 3):67-68.
127. Wegner S, Groen K, Aronson N, Barile A, Emmons W, Stephan K, Tasker S, Stoffels P, Verbiest W, Piotrovsky V, Larder B & Hertogs K. The potential role of resistance testing and therapeutic drug monitoring in the optimization of antiretroviral drug therapy. Antiviral Therapy 1999; 4 (Suppl. 1):77 (Abstr. 112).
128. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F & Brun-Vézinet F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Journal of the American Medical Association 2000; 283:205-211.
129. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP & Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. Journal of the American Medical Association 2000; 283:229-234.
130. Balzarini J & De Clercq E. Biochemical pharmacology of nucleoside analogs active against HIV. In Textbook of AIDS Medicine. Edited by S Broder, TC Jr Merigan & D Bolognesi. 1994; pp. 751-772. Baltimore: Williams & Wilkins.
131. Dianzani F, Antonelli G, Turriziani O, Riva E, Simeoni E, Signoretti C, Strosselli S & Cianfriglia M. Zidovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Research and Human Retroviruses 1994; 10:1471-1478.
132. Salomon H, Gu Z, Gao Q, Nagai K, Hiscott J & Wainberg MA. Host cell dependence of human immunodeficiency virus type-1 drug resistance profiles and tissue culture selection patterns. Antiviral Chemistry & Chemotherapy 1995; 6:222-229.
133. Magnani M, Gazzanelli G, Brandi G, Casabianca A, Fraternale A, Chiarantini L & Rossi L. 2′,3′-dideoxycytidine induced drug resistance in human cells. Life Sciences 1995; 57:881-887.
134. Peter K & Gambertoglio JG. Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus. Clinical Pharmacology and Therapeutics 1996; 60:168-176.
135. Durant J, Clevenbergh P & Garaffo R. Importance of protease inhibitor levels in patients treated with genotypic adapted therapy: pharmacalogical data from the VIRADAPT study. AIDS 2000; 14:1333-1339.
136. Acosta EP, Henry K, Baken L, Page LM & Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19:708-712.
137. Hoetelmans RM, Reijers MH, Weverling GJ, Ten Kate R, Wir FW, Mulder JW, Weigel HM, Frissen PH, Roos M, Jurriaans S, Schuitemaker H, de Wolf F, Beijnen JH van & Lange JM. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998; 12:F111-F115.
138. Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer S, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobson DM & Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. Journal of the American Medical Association 2000; 283:2417-2426.
139. th Annual Meeting of the Infectious Disease Society of America, Philadelphia, Pa., USA, 18-21 November 1999. Abstr. 320.
140. Bacheler LT, Anton B, Baker D, Becker M, Lasut A, Aujay M, Bolling L, Krakowski K, Bunville J, Wang V & Abremski K. Genotypic correlates of in vivo resistance to efavirenz. 6th Conference on Retroviruses and Opportunistic Infections., Chicago, Ill., USA, 31 January-4 February 1999. Abstr. 109.
141. Boyer PL, Lisziewicz J, Lori F & Hughes SH. Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase. Journal of Molecular Biology 1999; 286:995-1008.
142. Carrillo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, Kempf DJ & Molla A. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. Journal of Virology 1998; 72:7532-7541.
143. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, Aguado AG, De Lomas JG, Delgado R, BorLeffs JC, Hsu A, Valdes JM, Boucher CA & Cooper DA. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. New England Journal of Medicine 1995; 333:1528-1533.
144. Davey RJ, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, Eastman PS, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Boyle J, Coleman S, Cox SR, Wathen L, Daenzer CL & Lane HC. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrobial Agents & Chemotherapy 1996; 40:1657-1664.
145. De Noon DJ. AIDS Therapies. 1998. Atlanta: Charles W Henderson.
146. Gülick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA & Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 1997; 337:734-739.
147. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC & Hirsch MS. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. New England Journal of Medicine 1996; 335:1091-1098.
148. Larder B, Richman D & Vella S. HIV resistance and implications for therapy. 1998. Atlanta: Medicom Inc.
149. Lea AP & Faulds D. Stavudine. A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996; 51:846-864.
150. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM & Ho DD. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New England Journal of Medicine 1995; 333:1534-1539.
151. Patick AK, Duran M, Cao Y, Shugarts D, Keller MR, Mazabel E, Knowles M, Chapman S, Kuritzkes DR & Markowitz M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrobial Agents & Chemotherapy 1998; 42:2637-2644.
152. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C & Christopherson C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases 1995; 171:1411-1419.
153. Staszewski S, Harrigan PR, Stone C, Griffin P, Tortell S, Tisdale M & the CNAA 2002 International Project Group. Efficacy and resistance profile of abacavir at 24 and 48 weeks therapy including monotherapy and following switch to combination therapy (abacavir/zidovudine/lamivudine). Antiviral Therapy 1998; 3 (Suppl. 1):68.
154. th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 31 January-4 February 1999. Abstr. 118.
155. Lanier ER, Scott J, Steel H, Hetherington S, Ait-Khaled M, Pearce G, Spreen W & Lafon S. Multivariate analysis of predictors of response to abacavir: comparison of prior antiretroviral therapy, baseline HIV RNA, CD4 count and viral resistance. Antiviral Therapy 1999; 4 (Suppl. 1):56 (Abstr. 82).
156. Havlir D, Cheeseman SH, McLaughlin MM, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D , Myers M, Lamson M & Richman DD. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. Journal of Infectious Diseases 1995; 171:537-545.
157. Hammond J, Calef C, Larder B, Schinazi R & Mellors JW. Mutations in retroviral genes associated with drug resistance. In Human Retroviruses and AIDS. Edited by B Korber, C Kuiken, B Foley, B Hahn, F McCutchan, J Mellors & J Sodroski. 1998; pp. III-36-III-79. Los Alamos, N.M., USA: Theoretical Biology and Biophysics.